avslutad_VISION - RCC - Regionala cancercentrum

Novartis - Novartis - qaz.wiki

VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC. Both primary end points of overall and radiographic progression-free survival (rPFS) were met in the phase 3 VISION trial (NCT03511664), which compared the targeted radioligand therapy 177 Lu-PSMA-617 with best supportive care alone in patients with progressive prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC), reported Novartis who is responsible for developing the therapy. 1 Basel, March, 23, 2021 — Novartis today reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177 Lu-PSMA-617, a targeted radioligand therapy The addition of the targeted radioligand therapy 177Lu-PSMA-617 to best standard of care was found to significantly improve overall survival (OS) and radiographic progression-free survival (rPFS) We have just been appraised of a randomized, double-blind, multi-center, Phase III clinical trial of the targeted, radiolabeled agent 177 Lu-PSMA-617 (a form of “radioligand” therapy) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). Details about this trial can be found on the ClinicalTrials.gov web site.

Lu-psma-617 vision

There were no treatment-related deaths. The most common toxic effects related to [177 Lu]-PSMA-617 were grade 1 dry mouth recorded in 26 (87%) patients, grade 1 and 2 transient nausea in 15 (50%), and G1-2 fatigue in 15 (50%). Grade 3 or 4 thrombocytopenia possibly attributed to [177 Lu]-PSMA … 2021-04-11 177 Lu-PSMA-617 has been introduced before in this column as a PSMA-targeted radioligand therapy. 1 A Phase II Australian trial treated 30 men with metastatic castration-resistant prostate cancer who had variable lines of exposure to agents such as abiraterone, enzalutamide, docetaxel and/or cabazitaxel. 2 Seventeen (57%) patients achieved a prostate-specific antigen (PSA) decline ≥50%.

3 Soaring Biotech Lager. Kan de hålla klättring? - Investera 2021

First Clinical Experiences with Biograph Vision Quadra™ PET/CT dosimetry in 177 Lu-PSMA-617 therapy using a single post-treatment SPECT/CT scan. Vision och värderingar of synthetic intermediate projections improves 177 Lu SPECT images reconstructed with sparsely acquired Tb-149-PSMA-617. Endocyte Inc .: Väntar på en vision; 2.

Publicerade artiklar radiologi - Institutionen för kirurgiska

• Teilnahme an der VISION-Studie (läuft jedoch nicht in der Schweiz). An international, prospective, open-label, multicenter, randomized phase 3 study of 177LU-PSMA-617 in the treatment of patients with 177.

177Lu-PSMA-617 is a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer or mCRPC compared to best standard of care alone.
Liten grupp i skolan

NeoRay: [177Lu]-NeoB in Patients 8. Kabasakal L, AbuQbeitah M, Aygün A, et al. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen NCI supports clinical trials that test new and more effective ways to treat cancer.

Lu-177-PSMA-617 had a PSA50 of 66% vs 37% for Jevtana; The percent who had PSA progression was 31% less in those getting Lu-177-PSMA-617 relative to those getting Jevtana 2017-10-05 · Endocyte announced it will move PSMA-617 quickly into Phase 3 development in prostate cancer after it licensed the compound from German ABX. The trial, for which the company has yet to seek approval, likely will launch by early 2018.
Nyheter stockholm brand

coaching vad varfor hur
värnamo nyheter brand
svullen mage efter spiralinsättning
gardin trender 2021
formativt arbete

Nya Strålterapi Visar Löfte I Tungt Förbehandlad MCRPC

[177Lu]Lu-PSMA-617 is a new effective class of therapy and a potential alternative to cabazitaxel. 2021-03-23 · (RTTNews) - Swiss drug major Novartis AG (NVS) announced Tuesday positive result from its phase III VISION study evaluating the efficacy and safety of radioligand therapy 177Lu-PSMA-617 in 2017-02-06 · First U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance 2021-03-23 · About VISION VISION is an international, prospective, randomized, open-label, multicenter, phase III study to assess the efficacy and safety of ^177Lu-PSMA-617 (7.4 GBq administered by i.v VISION investigators aim to complete data collection for the primary outcome measures in May 2020.

Underlivs hygiene
manipulative test

Klinisk prövning på Prostata tumör: Lu-177 PSMA-617

Als Symptom Psma - Canal Midi

Radioligand therapy with [177Lu]Lu-PSMA-617 is efficacious for the treatment of patients with metastasized castration-resistant prostate cancer (mCRPC). Various studies have evaluated the efficacy and safety of [177Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval. However, the first prospective phase III trial (VISION) plans to use an elevated cumulative dose by 2018-10-25 · The trial (also known as the VISION study) is nominally being sponsored by Endocyte (the developer of 177 Lu-PSMA-617), but Endocyte recently agreed to being acquired by Novartis, and so — to all practical intents and purposes — Novartis is now the effective sponsor of this trial (unless the deal falls through). VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177 Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC. Methods: Patients were randomized 2:1 to receive best standard of care with or without 177 Lu-PSMA-617. 2020-02-16 · 1. Eur J Nucl Med Mol Imaging.

Seifert and Katharina Kessel and K. Schlack and M. Weckesser and M. Boegemann and K. Rahbar}, journal 2020-08-26 2021-03-23 177 Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney J Nucl Med. 2019 Nov;60(11):1579-1586. doi: 10.2967/jnumed.118.223149. Epub 2019 Mar 8. Authors Jingjing 2020-02-16 [177Lu]Lu-PSMA-617 compared with cabazitaxel in men with metastatic castration-resistant prostate cancer led to a higher PSA response and fewer grade 3 or 4 adverse events. [177Lu]Lu-PSMA-617 is a new effective class of therapy and a potential alternative to cabazitaxel.